# Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

> **NCT05025735** · PHASE2 · UNKNOWN · sponsor: **Saint Luke's Health System** · enrollment: 25 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Dapagliflozin 10Mg Tab

## Key facts

- **NCT ID:** NCT05025735
- **Lead sponsor:** Saint Luke's Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-25
- **Primary completion:** 2022-12
- **Final completion:** 2023-07
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2021-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025735, "Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05025735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*